# Arcutis Biotherapeutics, Inc.: financial statements, quarterly

ARQT · Nasdaq · CIK 1787306 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/arqt.md) · [Financials](/companies/arqt/financials.md) · [Filings](/companies/arqt/filings.md) · [Insiders](/companies/arqt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/arqt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [38.1](/filings/0001787306-24-000153.md) | [13.5 d](/filings/0001787306-26-000018.md) | [49.6](/filings/0001787306-25-000092.md) | [30.9](/filings/0001787306-25-000124.md) | [44.8](/filings/0001787306-25-000144.md) | [71.4 d](/filings/0001787306-26-000018.md) | [65.8](/filings/0001787306-26-000040.md) | [81.5](/filings/0001787306-26-000051.md) | [99.2](/filings/0001787306-25-000144.md) | [130 d](/filings/0001787306-26-000018.md) | [105](/filings/0001787306-26-000040.md) | [130](/filings/0001787306-26-000051.md) |
| Cost of revenue | $m | [1.2](/filings/0001787306-24-000153.md) | [2.2 d](/filings/0001787306-26-000018.md) | [3.3](/filings/0001787306-25-000092.md) | [3.5](/filings/0001787306-25-000124.md) | [5.5](/filings/0001787306-25-000144.md) | [6.9 d](/filings/0001787306-26-000018.md) | [8.8](/filings/0001787306-26-000040.md) | [7.5](/filings/0001787306-26-000051.md) | [8.7](/filings/0001787306-25-000144.md) | [11.7 d](/filings/0001787306-26-000018.md) | [9.8](/filings/0001787306-26-000040.md) | [10.9](/filings/0001787306-26-000051.md) |
| Research and development | $m | [26.2](/filings/0001787306-24-000153.md) | [23.8 d](/filings/0001787306-26-000018.md) | [23.1](/filings/0001787306-25-000092.md) | [19.3](/filings/0001787306-25-000124.md) | [19.5](/filings/0001787306-25-000144.md) | [14.5 d](/filings/0001787306-26-000018.md) | [17.5](/filings/0001787306-26-000040.md) | [19.5](/filings/0001787306-26-000051.md) | [19.6](/filings/0001787306-25-000144.md) | [20.5 d](/filings/0001787306-26-000018.md) | [30.6](/filings/0001787306-26-000040.md) | [20.4](/filings/0001787306-26-000051.md) |
| Selling, general and administrative | $m | [47.6](/filings/0001787306-24-000153.md) | [48.7 d](/filings/0001787306-26-000018.md) | [54.8](/filings/0001787306-25-000092.md) | [58.2](/filings/0001787306-25-000124.md) | [58.8](/filings/0001787306-25-000144.md) | [57.6 d](/filings/0001787306-26-000018.md) | [64.0](/filings/0001787306-26-000040.md) | [69.2](/filings/0001787306-26-000051.md) | [62.4](/filings/0001787306-25-000144.md) | [79.0 d](/filings/0001787306-26-000018.md) | [74.1](/filings/0001787306-26-000040.md) | [82.1](/filings/0001787306-26-000051.md) |
| Operating income | $m | [(36.9)](/filings/0001787306-24-000153.md) | [(61.2) d](/filings/0001787306-26-000018.md) | [(31.6)](/filings/0001787306-25-000092.md) | [(50.1)](/filings/0001787306-25-000124.md) | [(39.1)](/filings/0001787306-25-000144.md) | [(7.6) d](/filings/0001787306-26-000018.md) | [(24.5)](/filings/0001787306-26-000040.md) | [(14.6)](/filings/0001787306-26-000051.md) | [8.5](/filings/0001787306-25-000144.md) | [18.4 d](/filings/0001787306-26-000018.md) | [(9.1)](/filings/0001787306-26-000040.md) | [16.4](/filings/0001787306-26-000051.md) |
| Interest expense | $m | [7.6](/filings/0001787306-23-000124.md) | [7.8 d](/filings/0001787306-24-000031.md) | [7.5](/filings/0001787306-24-000079.md) | [7.5](/filings/0001787306-25-000124.md) | [6.7](/filings/0001787306-25-000144.md) | [5.6 d](/filings/0001787306-26-000018.md) | [3.0](/filings/0001787306-26-000040.md) | [3.0](/filings/0001787306-26-000051.md) | [3.1](/filings/0001787306-25-000144.md) | [3.0 d](/filings/0001787306-26-000018.md) | [4.4](/filings/0001787306-26-000040.md) | [3.4](/filings/0001787306-26-000051.md) |
| Income tax | $m | [3.0](/filings/0001787306-24-000153.md) | [0.0 d](/filings/0001787306-26-000018.md) | [0.3](/filings/0001787306-25-000092.md) | [0.0](/filings/0001787306-25-000124.md) | [0.0](/filings/0001787306-25-000144.md) | [0.3 d](/filings/0001787306-26-000018.md) | [0.3](/filings/0001787306-26-000040.md) | [0.3](/filings/0001787306-26-000051.md) | [0.1](/filings/0001787306-25-000144.md) | [0.5 d](/filings/0001787306-26-000018.md) | [0.1](/filings/0001787306-26-000040.md) | [0.1](/filings/0001787306-26-000051.md) |
| Net income | $m | [(44.8)](/filings/0001787306-24-000153.md) | [(66.3) d](/filings/0001787306-26-000018.md) | [(35.4)](/filings/0001787306-25-000144.md) | [(52.3)](/filings/0001787306-25-000144.md) | [(41.5)](/filings/0001787306-25-000144.md) | [(10.8) d](/filings/0001787306-26-000018.md) | [(25.1)](/filings/0001787306-26-000051.md) | [(15.9)](/filings/0001787306-26-000051.md) | [7.4](/filings/0001787306-25-000144.md) | [17.4 d](/filings/0001787306-26-000018.md) | [(11.3)](/filings/0001787306-26-000051.md) | [15.0](/filings/0001787306-26-000051.md) |
| Diluted EPS | $ per share | [(0.73)](/filings/0001787306-24-000153.md) | not reported | [(0.32)](/filings/0001787306-25-000092.md) | [(0.42)](/filings/0001787306-25-000124.md) | [(0.33)](/filings/0001787306-25-000144.md) | not reported | [(0.20)](/filings/0001787306-26-000040.md) | [(0.13)](/filings/0001787306-26-000051.md) | [0.06](/filings/0001787306-25-000144.md) | not reported | [(0.09)](/filings/0001787306-26-000040.md) | [0.11](/filings/0001787306-26-000051.md) |
| Basic EPS | $ per share | [(0.73)](/filings/0001787306-24-000153.md) | not reported | [(0.32)](/filings/0001787306-25-000092.md) | [(0.42)](/filings/0001787306-25-000124.md) | [(0.33)](/filings/0001787306-25-000144.md) | not reported | [(0.20)](/filings/0001787306-26-000040.md) | [(0.13)](/filings/0001787306-26-000051.md) | [0.06](/filings/0001787306-25-000144.md) | not reported | [(0.09)](/filings/0001787306-26-000040.md) | [0.11](/filings/0001787306-26-000051.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [107](/filings/0001787306-23-000124.md) | [88.4](/filings/0001787306-25-000029.md) | [190](/filings/0001787306-24-000079.md) | [84.3](/filings/0001787306-24-000124.md) | [135](/filings/0001787306-24-000153.md) | [71.3](/filings/0001787306-26-000018.md) | [53.1](/filings/0001787306-25-000092.md) | [72.7](/filings/0001787306-25-000124.md) | [47.1](/filings/0001787306-25-000144.md) | [42.9](/filings/0001787306-26-000051.md) | [34.8](/filings/0001787306-26-000040.md) | [34.1](/filings/0001787306-26-000051.md) |
| Current assets | $m | [282](/filings/0001787306-23-000124.md) | [330](/filings/0001787306-25-000029.md) | [468](/filings/0001787306-24-000079.md) | [435](/filings/0001787306-24-000124.md) | [424](/filings/0001787306-24-000153.md) | [336](/filings/0001787306-26-000018.md) | [324](/filings/0001787306-25-000092.md) | [333](/filings/0001787306-25-000124.md) | [349](/filings/0001787306-25-000144.md) | [411](/filings/0001787306-26-000051.md) | [438](/filings/0001787306-26-000040.md) | [468](/filings/0001787306-26-000051.md) |
| Total assets | $m | [293](/filings/0001787306-23-000124.md) | [341](/filings/0001787306-25-000029.md) | [479](/filings/0001787306-24-000079.md) | [445](/filings/0001787306-24-000124.md) | [437](/filings/0001787306-24-000153.md) | [349](/filings/0001787306-26-000018.md) | [344](/filings/0001787306-25-000092.md) | [352](/filings/0001787306-25-000124.md) | [371](/filings/0001787306-25-000144.md) | [433](/filings/0001787306-26-000051.md) | [460](/filings/0001787306-26-000040.md) | [489](/filings/0001787306-26-000051.md) |
| Current liabilities | $m | [41.9](/filings/0001787306-23-000124.md) | [46.7](/filings/0001787306-25-000029.md) | [47.3](/filings/0001787306-24-000079.md) | [51.4](/filings/0001787306-24-000124.md) | [172](/filings/0001787306-24-000153.md) | [81.0](/filings/0001787306-26-000018.md) | [91.1](/filings/0001787306-25-000092.md) | [104](/filings/0001787306-25-000124.md) | [99.8](/filings/0001787306-25-000144.md) | [130](/filings/0001787306-26-000051.md) | [163](/filings/0001787306-26-000040.md) | [160](/filings/0001787306-26-000051.md) |
| Total liabilities | $m | [246](/filings/0001787306-23-000124.md) | [253](/filings/0001787306-25-000029.md) | [254](/filings/0001787306-24-000079.md) | [258](/filings/0001787306-24-000124.md) | [281](/filings/0001787306-24-000153.md) | [191](/filings/0001787306-26-000018.md) | [201](/filings/0001787306-25-000092.md) | [213](/filings/0001787306-25-000124.md) | [213](/filings/0001787306-25-000144.md) | [243](/filings/0001787306-26-000051.md) | [270](/filings/0001787306-26-000040.md) | [268](/filings/0001787306-26-000051.md) |
| Long-term debt | $m | [201](/filings/0001787306-23-000124.md) | [202](/filings/0001787306-25-000029.md) | [203](/filings/0001787306-24-000079.md) | [204](/filings/0001787306-24-000124.md) | [105](/filings/0001787306-24-000153.md) | [107](/filings/0001787306-26-000018.md) | [108](/filings/0001787306-25-000092.md) | [107](/filings/0001787306-25-000124.md) | [107](/filings/0001787306-25-000144.md) | [108](/filings/0001787306-26-000051.md) | [101](/filings/0001787306-26-000040.md) | [102](/filings/0001787306-26-000051.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001787306-24-000153.md) | not reported | not reported | [99.5](/filings/0001787306-24-000153.md) | [0.0](/filings/0001787306-26-000018.md) | not reported | [1.0](/filings/0001787306-25-000124.md) | [1.0](/filings/0001787306-25-000144.md) | [1.0](/filings/0001787306-26-000051.md) | [8.0](/filings/0001787306-26-000040.md) | [7.0](/filings/0001787306-26-000051.md) |
| Shareholders' equity | $m | [46.7](/filings/0001787306-24-000153.md) | [88.7](/filings/0001787306-26-000018.md) | [225](/filings/0001787306-25-000144.md) | [186](/filings/0001787306-25-000144.md) | [157](/filings/0001787306-25-000144.md) | [158](/filings/0001787306-26-000051.md) | [143](/filings/0001787306-26-000051.md) | [139](/filings/0001787306-26-000051.md) | [158](/filings/0001787306-25-000144.md) | [189](/filings/0001787306-26-000051.md) | [190](/filings/0001787306-26-000051.md) | [221](/filings/0001787306-26-000051.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(44.0) d](/filings/0001787306-24-000153.md) | [(56.2) d](/filings/0001787306-26-000018.md) | [(31.6)](/filings/0001787306-25-000092.md) | [(45.1) d](/filings/0001787306-25-000124.md) | [(34.7) d](/filings/0001787306-25-000144.md) | [(0.7) d](/filings/0001787306-26-000018.md) | [(30.4)](/filings/0001787306-26-000040.md) | [0.3 d](/filings/0001787306-26-000051.md) | [(1.8) d](/filings/0001787306-25-000144.md) | [26.2 d](/filings/0001787306-26-000018.md) | [2.2](/filings/0001787306-26-000040.md) | [12.6 d](/filings/0001787306-26-000051.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001787306-24-000153.md) | [0.0 d](/filings/0001787306-26-000018.md) | [0.0](/filings/0001787306-25-000092.md) | [0.0 d](/filings/0001787306-25-000124.md) | [0.1 d](/filings/0001787306-25-000144.md) | [0.0 d](/filings/0001787306-26-000018.md) | [0.6](/filings/0001787306-26-000040.md) | [0.1 d](/filings/0001787306-26-000051.md) | [0.0 d](/filings/0001787306-25-000144.md) | [0.0 d](/filings/0001787306-26-000018.md) | [0.0](/filings/0001787306-26-000040.md) | [0.2 d](/filings/0001787306-26-000051.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [57.1](/filings/0001787306-23-000124.md) | [61.2](/filings/0001787306-24-000079.md) | [61.4](/filings/0001787306-24-000124.md) | [61.7](/filings/0001787306-24-000153.md) | [111](/filings/0001787306-25-000092.md) | [123](/filings/0001787306-25-000124.md) | [124](/filings/0001787306-25-000144.md) | [0.1](/filings/0001787306-26-000040.md) | [127](/filings/0001787306-26-000051.md) | [133](/filings/0001787306-25-000144.md) | [0.1](/filings/0001787306-26-000040.md) | [136](/filings/0001787306-26-000051.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 125,691,961 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001787306-26-000051.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.